The Gliptins, a new class of oral anti-diabetic drugs for type 2 diabetes mellitus, lower blood glucose
by inhibiting the enzyme dipeptidyl peptidase 4 and hence increasing the circulating levels of incretins (i.e gut
hormones which can boost insulin levels). This article reviews the current evidence on the effectiveness of
gliptins and suggest several ways in which these drugs could be used in type 2 diabetes mellitus treatment.